This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Top Message >> Message Archive (April 1, 2019)

PRINT

To Our Investors

Review of the status of development in the fiscal year 2018

Last fiscal year, we achieved the development of a large number of products, making strategic moves toward the future.
In the area of autologous cultured epidermis JACE, the indication was expanded to dystrophic and junctional epidermolysis bullosa, and in autologous cultured cartilage JACC, we received approval for the partial change application for simplification of transplantation method. Moreover, upon completion of the clinical trial on cultured autologous corneal epithelium, the application for marketing approval was promptly submitted. In addition, we have begun many development projects, making strategic moves toward the future. These include skin regeneration products that improve skin coloration abnormalities such as leukoderma, clinical trials to expand the indication for autologous cultured cartilage JACC to secondary osteoarthritis, the development of allogeneic culture epidermis, and the development of CAR-T cells as a new method of treating acute lymphocytic leukemia.

Management policy for the fiscal year 2019

In the fiscal year 2019, we will continue to implement the following goals on the basis of the last fiscal year’s achievements, as well as the strategic moves we have made toward the future.

Strive to expand the market for autologous cultured products and increase our corporate value

We will expand the market of autologous cultured epidermis JACE by providing a new treatment option to patients with dystrophic and junctional epidermolysis bullosa. As a result of simplifying transplantation method with autologous cultured cartilage JACC, we are convinced that we can bring satisfaction to both the patients undergoing treatment and the doctors who treat them. In addition, we will create treatment opportunities for patients with osteoarthritis. While aiming to expand the regenerative medicine market, we will go on pursuing the goals that only we can accomplish.

Expand our business opportunities through contract projects

We will increase our business opportunities in regenerative medicine by engaging in contract projects (custom development and manufacturing business). Commissioned by FUJIFILM, we have been supporting the meniscal repair therapy that had been under development by Tokyo Medical and Dental University, and its overview was released in March (Click here for details). Many of the patients with diseases of the knee joint suffer from problems with the meniscus, and we think there will be a growing number of opportunities for our company to be active in this area. This fiscal year we will strive to expand new business opportunities through related contract projects, polishing and enhancing the technology that is entrusted to us, and providing therapies that will bring satisfaction to the patients.

Set a new standard for regenerative medical products

Last fiscal year, we drew upon all of our experience over the past 20 years to work out a new concept and plan for the company. We would like to become the ideal developer, producer, and marketer of regenerative medical products that we aspire to be in this fiscal year.
Our regenerative medicine is still only available to a limited number of people. This fiscal year, we aim to steadily proceed with preparations for the final stage to implement all aspects of the growth strategies I mentioned at the beginning.

Welcoming new members

This fiscal year, 6 new members joined us. They are all wonderful young people. My responsibilities have become heavier by at least 6 members’ worth. However, they will breathe new air into the company and bring happiness above and beyond that. In the near future, I would like to complete constructing the magnificent stage of the regenerative medicine industry so that they can fully play their role as fine “ambassadors of regenerative medicine”.
6 new members

April 1, 2019
Kenichiro Hata
President & CEO
Japan Tissue Engineering Co., Ltd.